Who can make a custom batch of THR-123?

Peppers2

Peppers2

Explorer
Joined
Oct 23, 2025
Messages
5
Reaction score
0
Location
Florida United States
Hi there -

Any idea who might be able to manufacture a peptide that normal vendor lists do not carry? I would like the one below made up, since studies have shown it reversing diabetes. Thrasos made it for AKI, then shelved it once results fell short of what they wanted.

THR-123 is a cyclic peptide of 16 amino acids, a BMP-7 mimetic (ALK3 agonist). Chemical Breakdown

  • One-letter code: CYFDDSSNVLCKKYRS
  • Written out in full: Cys-Tyr-Phe-Asp-Asp-Ser-Ser-Asn-Val-Leu-Cys-Lys-Lys-Tyr-Arg-Ser
  • Ring closure: Disulfide bridge between Cys1 and Cys11.
  • Free-base formula: C₈₃H₁₂₄N₂₂O₂₇S₂
  • Mass: 1926.13 Da (free base)
  • Shorthand listing: Often listed as CYFDDSSNVLCKKYRS (Cys1-Cys11 disulfide)
 
https://www.medchemexpress.com/thr-...b3HZkLVsX98Tgb7apJEXx3FPgmgW_AC_B-dfuB5JAyLDW

Bulk quantities of this are already being sold. A peptide sequencer doesn't cost that much. What drives up the cost in production is the purification step that comes afterward, which relies on liquid chromatography.

Following that, you'd have to prepare a liquid formulation, put it into vials, and then run it through a lyophilizer.

With the right resources, all of this can be done. The problem is the price would be extremely high.

Economy of scale governs peptide production, meaning costs drop as output rises.

"THR-123" looks like a relatively recent compound. So far I've only come across phase one trials (safety). Holding off until phase two trial (efficacy) data begins to appear might be worthwhile. Waiting could pay off, or it could end up resembling AOD-9604, which delivered results in rats but looked less encouraging in humans.

Sadly, given how the pharmaceutical business operates in the USA, a lifetime subscription always brings more incentive than a cure.
 
Indeed, THR-184 was another compound developed by Thrasos, and it did reach phase II human testing; as far as I know, though, the THR-123 variant has never been tested in people. Regarding THR-123 and human applicability: the relevant pathways remained conserved in human pancreatic slices, and prior BMP-7 studies had already demonstrated beta-cell regeneration in T1D donor tissue ex vivo.

THR-184 → a later, optimized iteration; it progressed into Phase 1/2 clinical trials aimed at preventing acute kidney injury (AKI) associated with cardiac surgery.

Research into THR-123 for diabetes focuses on whether it can regenerate insulin-producing pancreatic beta cells in situ (directly inside the pancreas) as a drug-based strategy for treating insulin-dependent diabetes, especially type 1 diabetes (T1D).
 
Standard research vendors do appear to carry it, though convincing them to actually sell it to you could prove difficult — a doctorate plus a lab shipping address tends to be the requirement. Custom synthesis is an option, but expect a hefty price tag, and you may hit the same wall of lab-only supply. Those "dodgy" outfits that move peptides for therapeutic use while labeling them not for human use typically stock only a narrow catalog.

If you genuinely intend to take a compound at this point in its development, serious homework on the associated problems and dangers would be essential. Phase 1 trials do filter out certain risks, yet they won't catch rarer side effects or those appearing over the long term.
 
Back
Top